Skip to main content
ALVO logo

ALVO · Alvotech

Track ALVO — free
$4.06 -0.04 (-0.86%) At close · Aug 14
Market Cap
$1.37B
Shares
338.22M

Alvotech Earnings Call Transcripts

Every quarterly earnings call for Alvotech (ALVO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q4
2027-03-11
Q4 2026 Earnings Call (Full Year)
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-11-12
Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-20
Q2 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference Miami 2026
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference New York 2026
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-31
Alvotech Q1 FY2026 Earnings Call
Positive tone Pipeline submissions and approvals FDA inspection and BLA resubmissions Geographic expansion
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Alvotech Q3 FY2025 Earnings Call
Positive tone FDA Complete Response Letter for Simponi biosimilar Biosimilar pipeline and development programs Reykjavik facility inspection and remediation
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Alvotech Q2 FY2025 Earnings Call
Confident tone Financial performance and growth Humira biosimilar (SIMLANDI/HUKYNDRA) STELARA biosimilar (AVT04)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Alvotech Q1 FY2025 Earnings Call
Confident tone Stelara biosimilar launch and interchangeable designation Humira / SIMLANDI commercial performance Capacity / manufacturing scale
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Alvotech Q3 FY2024 Earnings Call
Confident tone Pipeline Advancement 2025 Revenue Guidance FDA Inspection and Compliance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Alvotech Q2 FY2024 Earnings Call
Confident tone US Humira (adalimumab) biosimilar ramp Pipeline expansion and upcoming submissions Stelara biosimilar (SELARSDI / AVT04)
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Alvotech Q1 FY2024 Earnings Call
Confident tone Humira biosimilar (AVT02) U.S. launch Stelara biosimilar (AVT04/Selarsdi) global launches Pipeline expansion and new filings
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Alvotech Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Alvotech Q3 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Alvotech Q2 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Alvotech Q1 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Alvotech Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Alvotech Q3 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Alvotech Q2 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–19 of 19 earnings calls
Key facts CIK 1898416 CUSIP L01800108 13F (30d) 74 filings 73 filers Visit website Investor relations